Abstract
In an aging population vascular disorders well exemplified by the chronic limb ischemia, chronic heart failure, cerebral ischemia and age-related macular degeneration represent a serious medical and socio-economical problem. While there is always a not easily identifiable first pathogenic noxa, all of these diseases are characterized by ischemia, chronic inflammation and tissue degeneration. Orthodox medicine has provided several optimal drugs targeting various pathological situations but, even with their concomitant applications, it is not possible to reduce the chronic oxidative stress. Here it is proposed to associate the approach of ozonated autohemotherapy as a modifier of the biological response capable to block the pathological progress.
Keywords: Chronic limb ischemia, chronic heart failure, ictus, age-related macular degeneration, chronic oxidative stress, ozone therapy
Cardiovascular & Hematological Disorders-Drug Targets
Title: May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?
Volume: 9 Issue: 2
Author(s): Velio Bocci, Valter Travagli and Iacopo Zanardi
Affiliation:
Keywords: Chronic limb ischemia, chronic heart failure, ictus, age-related macular degeneration, chronic oxidative stress, ozone therapy
Abstract: In an aging population vascular disorders well exemplified by the chronic limb ischemia, chronic heart failure, cerebral ischemia and age-related macular degeneration represent a serious medical and socio-economical problem. While there is always a not easily identifiable first pathogenic noxa, all of these diseases are characterized by ischemia, chronic inflammation and tissue degeneration. Orthodox medicine has provided several optimal drugs targeting various pathological situations but, even with their concomitant applications, it is not possible to reduce the chronic oxidative stress. Here it is proposed to associate the approach of ozonated autohemotherapy as a modifier of the biological response capable to block the pathological progress.
Export Options
About this article
Cite this article as:
Bocci Velio, Travagli Valter and Zanardi Iacopo, May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?, Cardiovascular & Hematological Disorders-Drug Targets 2009; 9 (2) . https://dx.doi.org/10.2174/187152909788488681
DOI https://dx.doi.org/10.2174/187152909788488681 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Mitochondrial Dysfunction in Type 2 Diabetes
Current Pharmaceutical Design Safety Analysis and Improved Cardiac Function Following Local Autologous Transplantation of CD133+ Enriched Bone Marrow Cells After Myocardial Infarction
Current Neurovascular Research TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Phase I Clinical Trial of Exherin (ADH-1) in Patients with Advanced Solid Tumors
Current Clinical Pharmacology Research Toward Potassium Channels on Tumor Progression
Current Topics in Medicinal Chemistry Toxicity of Carbon Nanotubes
Current Drug Metabolism Recent Advances in Pulmonary Hypertension Therapy
Recent Patents on Cardiovascular Drug Discovery The Potential of Microalgae for the Production of Bioactive Molecules of Pharmaceutical Interest
Current Pharmaceutical Biotechnology The LIM Protein fhlA is Essential for Heart Chamber Development in Zebrafish Embryos
Current Molecular Medicine Poor Response to Antiplatelet Drugs. An Important Issue in Drug-Eluting Stents.
Current Clinical Pharmacology The Ryanodine Receptor: A Pivotal Ca2+ Regulatory Protein and Potential Therapeutic Drug Target
Current Drug Targets Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
Current Diabetes Reviews CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Glycogen Synthase Kinase-3 (GSK-3) Inhibitors as a New Lead for Treating Breast and Ovarian Cancer
Current Drug Targets Bedtime Hypertension Chronotherapy: Concepts and Patient Outcomes
Current Pharmaceutical Design Natural Products of Dietary Origin as Lead Compounds in Virtual Screening and Drug Design
Current Pharmaceutical Biotechnology LPS In Patients With Left Ventricular Dysfunction Of Ischemic And Non-Ischemic Origin
Cardiovascular & Hematological Disorders-Drug Targets Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry Toll-like Receptor as a Molecular Link between Metabolic Syndrome and Inflammation: A Review
Current Drug Targets Protein Kinase C Isozyme Selective Peptides - A Current View of What they Tell Us About Location and Function of Isozymes in the Heart
Current Pharmaceutical Design